GlassScriptPhysician profile
Sarah Hart
NPI 1669197331
$671.43
in general payments reported to CMS, 2019-2025
11 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $410 · 2024: $44.13 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $142.08 | 2023 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $132.90 | 2023 | |
| Exact Sciences Corporation | $130.05 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $58.75 | 2024-2025 | |
| Organon LLC | $53.55 | 2024-2025 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.84 | 2023 | Xifaxan |
| Novo Nordisk INC | $34.12 | 2023 | |
| Corium, LLC | $29.65 | 2023 | Azstarys |
| Mirum Pharmaceuticals, INC. | $18.64 | 2025 | Livmarli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.46 | 2023 | Jardiance |
| Amgen INC. | $16.39 | 2023 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.